Drug Trial Radar · NCT07937748
Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jan 1, 2029
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chiesi USA, Inc.
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 days, up to 5 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size, disease activity, pain, and family burden during and after treatment.
Conditions
- Dystrophic Epidermolysis Bullosa
- Junctional Epidermolysis Bullosa
Interventions
Filsuvez topical gel: 10% birch triterpenesDrug
Filsuvez topical gel: 10% birch triterpenes w/w in a colorless, slightly yellow gel supplied in 25 mL sterile tubes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the safety and tolerability of FilsuvezTime frame: 450 days-including follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.